yndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Cyclosporine: Avoid the concomitant use of venetoclax and cyclosporine; venetoclax is a substrate of CYP3A4, P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP) and cyclosporine is an inhibitor of CYP3A4 (moderate), P-gp, and BCRP. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If cyclosporine is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Dabrafenib: Avoid the concomitant use of venetoclax and dabrafenib; venetoclax levels may be decreased and its efficacy reduced. Venetoclax is a CYP3A4 substrate and dabrafenib is a moderate CYP3A4 inducer. Consider alternative agents. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were decreased by 42% and 71%, respectively, following the co-administration of multiple doses of a strong CYP3A4 inducer. Use of venetoclax with a moderate CYP3A4 inducer has not been eva luated.
Daclatasvir: Avoid the concomitant use of venetoclax and daclatasvir. Venetoclax is a substrate of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); daclatasvir is an inhibitor of P-gp and BCRP. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If daclatasvir is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Dalfopristin; Quinupristin: Avoid the concomitant use of venetoclax and dalfopristin; quinupristin. Venetoclax is a CYP3A4 substrate and quinupristin is a strong CYP3A4 inhibitor. The concomitant use of these agents together is contraindicated during the initial and dose titration phase of venetoclax. If concomitant use of these drugs is required when the patient is on a steady venetoclax dose (after the titration phase), reduce the venetoclax dosage by at least 75% (maximum dose of 100 mg/day). If dalfopristin; quinupristin is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study, the venetoclax Cmax and AUC values were increased by 2.3-fold and 6.4-fold, respectively, when a strong CYP3A4 inhibitor was co-administered in NHL patients.
Darunavir: Avoid the concomitant use of venetoclax and darunavir; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and darunavir is a CYP3A4 (moderate) and P-gp inhibitor. Consider alternative agents. If concomita |
